| Zacks Company Profile for Sanofi (SNY : NSDQ) |
|
|
| |
| • Company Description |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Number of Employees: 82,878 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $48.31 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,084,311 shares |
| Shares Outstanding: 2,452.46 (millions) |
| Market Capitalization: $118,478.43 (millions) |
| Beta: 0.49 |
| 52 Week High: $60.12 |
| 52 Week Low: $45.80 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-1.79% |
-6.05% |
| 12 Week |
-4.83% |
-22.35% |
| Year To Date |
0.17% |
-5.05% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
46 AVENUE DE LA GRANDE ARMEE
-
PARIS,I0 75017
FRA |
ph: 33-1-53-77-44-00
fax: 33-1-53-77-43-03 |
ir@sanofi.com |
http://www.sanofi.com |
|
|
| |
| • General Corporate Information |
Officers
Paul Hudson - Chief Executive Officer
Frederic Oudea - Chairman of the Board
Olivier Charmeil - Executive Vice President; Chief Financial Officer
Brian Foard - Director
Emmanuel Frenehard - Director
|
|
Peer Information
Sanofi (AGN.)
Sanofi (NVS)
Sanofi (NVO)
Sanofi (LLY)
Sanofi (RHHBY)
Sanofi (JNJ)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 80105N105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/31/25
|
|
Share - Related Items
Shares Outstanding: 2,452.46
Most Recent Split Date: (:1)
Beta: 0.49
Market Capitalization: $118,478.43 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 3.31% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.97 |
Indicated Annual Dividend: $1.60 |
| Current Fiscal Year EPS Consensus Estimate: $4.56 |
Payout Ratio: 0.36 |
| Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: 0.02 |
| Estmated Long-Term EPS Growth Rate: 10.65% |
Last Dividend Paid: 05/09/2025 - $1.60 |
| Next EPS Report Date: 07/31/25 |
|
|
|
| |
